NKMax America Revenue and Competitors
Estimated Revenue & Valuation
- NKMax America's estimated annual revenue is currently $13.9M per year.
- NKMax America's estimated revenue per employee is $155,000
- NKMax America's total funding is $11M.
Employee Data
- NKMax America has 90 Employees.
- NKMax America grew their employee count by -5% last year.
NKMax America's People
Name | Title | Email/Phone |
---|---|---|
1 | CTO | Reveal Email/Phone |
2 | VP Marketing | Reveal Email/Phone |
3 | Director, Regulatory Affairs | Reveal Email/Phone |
NKMax America Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 4 | -50% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is NKMax America?
NKMax America is harnessing the power of the body's immune system through the development of unique Natural Killer (NK) cell therapies. NK cell adoptive immunotherapy enhances a patient's ability to destroy abnormal cells. The mission of NKMax is to improve patients' lives in a safe and natural way through innovative cell therapy products and to ultimately become the global leader in immune cell therapeutics. More information can be found on our website www.nkmaxamerica.com
keywords:N/A$11M
Total Funding
90
Number of Employees
$13.9M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $12.8M | 90 | 17% | N/A |
#2 | $13.7M | 90 | 23% | N/A |
#3 | $22.1M | 90 | 7% | N/A |
#4 | $33.6M | 92 | 21% | N/A |
#5 | $16.1M | 92 | 35% | N/A |